Stock listing
A3EQWL Stock Price, News, Filings & Events — Mira Pharmaceuticals, Inc.
Selected listing: A3EQWL · LS · EUR · DE
This page tracks Mira Pharmaceuticals, Inc.'s A3EQWL:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A3EQWL:LS. A3EQWL:LS is the stock-level entry point for investors researching Mira Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A3EQWL:LS
- Asset type
- Stock
- Market cap
- $31.5M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Other
- Exchange
- LS
- Currency
- EUR
Mira Pharmaceuticals, Inc. A3EQWL:LS stock context
This page tracks Mira Pharmaceuticals, Inc.'s A3EQWL:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A3EQWL:LS. A3EQWL:LS is the stock-level entry point for investors researching Mira Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Mira Pharmaceuticals, Inc.
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
September 1, 2026
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
July 30, 2026
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic In...
July 10, 2026
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction
July 6, 2026
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
June 17, 2026
Research Mira Pharmaceuticals, Inc.
Mira Pharmaceuticals, Inc. investor report
Review AI stock analysis and investor report context for A3EQWL:LS.
Mira Pharmaceuticals, Inc. company profile
View the public company page for Mira Pharmaceuticals, Inc. on 6ix.
Mira Pharmaceuticals, Inc. news
Read company news and market updates connected to Mira Pharmaceuticals, Inc..
Mira Pharmaceuticals, Inc. investor events
Find investor webinars, events, and replay context for Mira Pharmaceuticals, Inc..
Alternate listings
MIRA:NASDAQ
US · USD
Alternate listing for Mira Pharmaceuticals, Inc.; the primary context on this page is A3EQWL:LS.
K6S:GETTEX
DE · EUR
Alternate listing for Mira Pharmaceuticals, Inc.; the primary context on this page is A3EQWL:LS.
A3EQWL:LSX
DE · EUR
Alternate listing for Mira Pharmaceuticals, Inc.; the primary context on this page is A3EQWL:LS.
MIRA:BOATS
US · USD
Alternate listing for Mira Pharmaceuticals, Inc.; the primary context on this page is A3EQWL:LS.
K6S:TRADEGATE
DE · EUR
Alternate listing for Mira Pharmaceuticals, Inc.; the primary context on this page is A3EQWL:LS.
K6S:DUS
DE · EUR
Alternate listing for Mira Pharmaceuticals, Inc.; the primary context on this page is A3EQWL:LS.
K6S:FWB
DE · EUR
Alternate listing for Mira Pharmaceuticals, Inc.; the primary context on this page is A3EQWL:LS.
K6S:HAM
DE · EUR
Alternate listing for Mira Pharmaceuticals, Inc.; the primary context on this page is A3EQWL:LS.
K6S:MUN
DE · EUR
Alternate listing for Mira Pharmaceuticals, Inc.; the primary context on this page is A3EQWL:LS.
K6S:SWB
DE · EUR
Alternate listing for Mira Pharmaceuticals, Inc.; the primary context on this page is A3EQWL:LS.